DLP may be able to treat NAFLD by reducing oxidative stress in liver cells and controlling ferroptosis because increased levels of GPX4 and ferritin heavy chain FTH1 mRNA and protein expression can reduce the levels of the key ferroptosis-related protein iron response element binding protein 2 (IREB2) in the liver (91). Here, GPX4 is linked to metabolic dysfunction-associated steatotic liver disease.